Cascadian Therapeutics (CASC) Misses Q2 EPS by 4c
Tweet
Share
E-mailGet Alerts CASC Hot Sheet
Join SI Premium – FREE
Cascadian Therapeutics (NASDAQ: CASC) reported Q2 EPS of ($0.30), $0.04 worse than the analyst estimate of ($0.26).
For earnings history and earnings-related data on Cascadian Therapeutics (CASC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
- Laser Photonics Corporation (LASE) Reports Q2 Loss of $0.08
- LeonaBio, Inc. (LONA) Tops Q2 EPS by 32c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
